- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Imatron expects record 1994 revenues
CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure
CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure of$25.1 million. Net income for 1994 should be $2.3 million, versusa loss of $2.9 million in 1993.
Imatron has enjoyed strong sales of its C-150 Ultrafast CTscanner in recent months. Imatron received an order in Decemberfor 10 C-150 units from Imatron Japan in a transaction worth $16million (SCAN 12/28/94). Revenue from that sale will registerin the company's 1995 and 1996 fiscal years.
Imatron's backlog is at its highest level since the companywas formed in 1983, president and CEO Lewis Meyer said. The backlogshould help the firm register revenues of over $40 million in1995.
This year Imatron will embark on a major expansion of its HeartScanImaging clinics, which provide coronary artery screening directlyto the public (SCAN 4/6/94). Imatron plans to open clinics inSeattle, Houston and Washington, DC.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
